Product Description: DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity[1][2][3].
Applications: Cancer-programmed cell death
Formula: C29H29Cl3FN3O4
References: [1]Zhao Yizhaiteng, et al. Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor. WO2016052697A1./[2]Nakagawa M, et al. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. Oncogene. 2019 Oct;38(42):6835-6849./[3]Matsunaga H, et al. Characterization of a novel BBB-permeable mutant IDH1 inhibitor, DS-1001b. Annals of Oncology, 2019, 30: v145-v146.
CAS Number: 1898207-64-1
Molecular Weight: 608.92
Compound Purity: 99.71
Research Area: Cancer
Solubility: DMSO : 29 mg/mL (ultrasonic)
Target: Isocitrate Dehydrogenase (IDH)
English
Deutsch
